Cantex Pharmaceuticals Receives FDA Orphan Drug Designation For Azeliragon For The Treatment Of Pancreatic Cancer; Azeliragon Was Discovered By And Originally Under Development For Alzheimer's Disease By Vtv Therapeutics, Which Cantex Licensed Worldwide Rights

Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Cantex' azeliragon, a well-tolerated once-a-day pill, for the treatment of pancreatic cancer. This new azeliragon orphan drug designation adds to azeliragon's previous orphan drug designation for the treatment of glioblastoma, received in early 2023.